EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

Anetta Marcinek, Bettina Brauchle, Lisa Rohrbacher, Gerulf Hänel, Nora Philipp, Florian Märkl, Thaddäus Strzalkowski, Sonja M Lacher, Dragica Udiljak, Karsten Spiekermann, Sebastian Theurich, Sebastian Kobold und 4 weitere

Cancer Immunology, Immunotherapy · 2023

DOI: 10.1007/s00262-023-03439-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Anetta Marcinek und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Elitenetzwerk Bayern, Wilhelm Sander-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bispecific T-cell engager (BiTE ® ) molecules recruit T cells to cancer cells through CD3ε binding, independently of T-cell receptor (TCR) specificity. Whereas physiological T-cell activation is dependent on signal 1 (TCR engagement) and signal 2 (co-stimulation), BiTE molecule-mediated T-cell activation occurs without additional co-stimulation. As co-stimulatory and inhibitory molecules modulate the strength and nature of T-cell responses, we studied the impact of the expression profile of those molecules on target cells for BiTE molecule-mediated T-cell activation in the context of acute myeloid leukemia (AML). Accordingly, we created a novel in vitro model system using murine Ba/F3 cells transduced with human CD33 ± CD86 ± PD-L1. T-cell fitness was assessed by T-cell function assays in co-cultures and immune synapse formation by applying a CD33 BiTE molecule (AMG 330). Using our cell-based model platform, we found that the expression of positive co-stimulatory molecules on target cells markedly enhanced BiTE molecule-mediated T-cell activation. The initiation and stability of the immune synapse between T cells and target cells were significantly increased through the expression of CD86 on target cells. By contrast, the co-inhibitory molecule PD-L1 impaired the stability of BiTE molecule-induced immune synapses and subsequent T-cell responses. We validated our findings in primary T-cell-AML co-cultures, demonstrating a PD-L1-mediated reduction in redirected T-cell activation. The addition of the immunomodulatory drug (IMiD) lenalidomide to co-cultures led to stabilization of immune synapses and improved subsequent T-cell responses. We conclude that target cells modulate CD33 BiTE molecule-dependent T-cell activation and hence, combinatorial strategies might contribute to enhanced efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificLeukemia, Myeloid, AcuteAnimalsHumansMiceB7-H1 AntigenImmune Checkpoint ProteinsReceptors, Antigen, T-CellSialic Acid Binding Ig-like Lectin 3T-Lymphocytes

Stichwörter der Autor:innen

Acute myeloid leukemiaBispecific antibodiesCheckpoint molecule (PD-L1)Costimulation (CD86)Immune synapse

Substanzen

Antibodies, BispecificB7-H1 AntigenCD33 protein, humanImmune Checkpoint ProteinsReceptors, Antigen, T-CellSialic Acid Binding Ig-like Lectin 3

Autor:innen und Institutionen

  • Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
  • Division of Clinical Pharmacology, Department of Medicine IV; Member of the German Center for Lung Research (DZL), University Hospital, LMU, Munich, Germany.
  • German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Experimental Leukemia and Lymphoma Research (ELLF), Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Cancer-and Immunometabolism Research Group, LMU Gene Center, Munich, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • Elitenetzwerk Bayern
  • Wilhelm Sander-Stiftung
  • Else Kröner-Fresenius-Stiftung
  • Universitätsklinik München

Zitieren

APA

Marcinek, A., Brauchle, B., Rohrbacher, L., Hänel, G., Philipp, N., Märkl, F., Strzalkowski, T., Lacher, S. M., Udiljak, D., Spiekermann, K., Theurich, S., Kobold, S., Kischel, R., James, J. R., Bücklein, V. L., & Subklewe, M. (2023). CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03439-x

Vancouver

Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, et al. CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03439-x

BibTeX
@article{Marcinek2023,
  author = {Marcinek, Anetta and Brauchle, Bettina and Rohrbacher, Lisa and Hänel, Gerulf and Philipp, Nora and Märkl, Florian and Strzalkowski, Thaddäus and Lacher, Sonja M and Udiljak, Dragica and Spiekermann, Karsten and Theurich, Sebastian and Kobold, Sebastian and Kischel, Roman and James, John R and Bücklein, Veit L and Subklewe, Marion},
  title = {CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  doi = {10.1007/s00262-023-03439-x}
}
Kostenlos starten →